Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastoma
Chiwoo Kim (Kim C), Young Bae Choi (Choi YB), Ji Won Lee (Lee JW), Keon Hee Yoo (Yoo KH), Ki Woong Sung (Sung KW), Hong Hoe Koo (Koo HH)
Clin Exp Pediatr. 2018;61(2):53-58.   Published online 2018 Feb 28     DOI: https://doi.org/10.3345/kjp.2018.61.2.53
Citations to this article as recorded by Crossref logo
A Survey on Publicly Available Open Datasets Derived From Electronic Health Records (EHRs) of Patients with Neuroblastoma
Davide Chicco, Gabriel Cerono, Davide Cangelosi
Data Science Journal.2022; 21(1): 17.     CrossRef
Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification
Frank Berthold, Carolina Rosswog, Holger Christiansen, Michael Frühwald, Nadine Hemstedt, Thomas Klingebiel, Birgit Fröhlich, Freimut H. Schilling, Irene Schmid, Thorsten Simon, Barbara Hero, Matthias Fischer, Angela Ernst
Pediatric Blood & Cancer.2021;[Epub]     CrossRef
Innovative therapies for neuroblastoma: The surprisingly potent role of iron chelation in up-regulating metastasis and tumor suppressors and down-regulating the key oncogene, N-myc
Tharushi P. Wijesinghe, Mahendiran Dharmasivam, Charles C. Dai, Des R. Richardson
Pharmacological Research.2021; 173: 105889.     CrossRef
Incidence and Prognostic Role of the Ocular Manifestations of Neuroblastoma in Children
Sybille Graef, Meredith S. Irwin, Michael J. Wan
American Journal of Ophthalmology.2020; 213: 145.     CrossRef
Antineoplastics
Reactions Weekly.2018; 1694(1): 41.     CrossRef